Clinical and immunologic impact of short-course enzalutamide alone and with immunotherapy in non-metastatic castration sensitive prostate cancer

BACKGROUND: The standard treatment for non-metastatic castration sensitive prostate cancer (nmCSPC) is androgen deprivation therapy (ADT) or surveillance. This study evaluated the potential synergy of immunotherapy and enzalutamide (without ADT) in nmCSPC. In addition, the immunologic impact of enza...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:J Immunother Cancer
Egile Nagusiak: Madan, Ravi A, Karzai, Fatima, Donahue, Renee N, Al-Harthy, Munjid, Bilusic, Marijo, Rosner, Inger I, Singh, Harpreet, Arlen, Philip M, Theoret, Marc R, Marté, Jennifer L, Cordes, Lisa, Couvillon, Anna, Hankin, Amy, Williams, Moniquea, Owens, Helen, Lochrin, Sarah E, Chau, Cindy H, Steinberg, Seth, Figg, William Douglas, Dahut, William, Schlom, Jeffrey, Gulley, James L
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BMJ Publishing Group 2021
Gaiak:
Clinical/Translational Cancer Immunotherapy
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7934713/
https://ncbi.nlm.nih.gov/pubmed/33664086
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-001556
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak